StockData
Tempest Therapeutics, Inc. logo

Tempest Therapeutics, Inc. (TPST) stock

TPSTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 4/30
$0.33−0.01 (-4.24%)

Close on Nov 17, 2026Market cap $4.85MP/E –Yield –

Tempest Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Tempest Therapeutics's revenue for the twelve months ending Sep 30, 2018 was $294.00K, down 9.3% year over year. For fiscal 2017 it was $295.00K, down 54.8% from the year before. The highest annual figure on record is $653.00K in fiscal 2016.

Annual revenue

PeriodPeriod endValueChange
FY2017Dec 31, 2017$295.00K-54.8%
FY2016Dec 31, 2016$653.00K+135.7%
FY2015Dec 31, 2015$277.00K–
FY2014Dec 31, 2014$0–
FY2013Dec 31, 2013$0–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2018Sep 30, 2018$55.00K-1.8%
Q2 FY2018Jun 30, 2018$81.00K-3.6%
Q1 FY2018Mar 31, 2018$67.00K+6.3%
Q4 FY2017Dec 31, 2017$91.00K-24.8%
Q3 FY2017Sep 30, 2017$56.00K-71.6%
Q2 FY2017Jun 30, 2017$84.00K–
Q1 FY2017Mar 31, 2017$63.00K–
Q4 FY2016Dec 31, 2016$121.00K–
Q3 FY2016Sep 30, 2016$197.00K–

More Tempest Therapeutics figures

See a number that looks wrong?